Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Covidien Introduces New Surgical Device for Meniscal Repair



  Covidien Introduces New Surgical Device for Meniscal Repair

  AS Meniscal™ Repair Device Combines Best Surgical Techniques for Repairing
                                Meniscus Tears

Business Wire

NEW HAVEN, Conn. -- December 04, 2012

Covidien (NYSE: COV), a leading global provider of healthcare products, today
announced the launch of the AS Meniscal™ Repair Device. The newest addition to
the Company’s line of sports surgery devices, the AS Meniscal Repair Device
enables orthopedic surgeons to perform “all-inside,” minimally invasive
arthroscopic surgery to repair a torn meniscus in the knee using the gold
standard “all-suture” method of fixation.

“Any meniscal repair system needs to deliver high-strength fixation in order
to optimize the biologic healing potential,” said Bryan M. Huber, MD, Board
Certified Orthopedic Surgeon at Mansfield Orthopaedics in Stowe, Vermont. “The
AS Meniscal Repair Device enables surgeons to leverage the value of using the
gold standard all-suture approach in a less invasive arthroscopic fashion.”

Bench-top tests conducted by Covidien confirm that the AS Meniscal Repair
Device deploys sutures with strong holding power consistently and reliably
without the need for any anchors^1.

Dr. Huber added, “In my practice, I have experienced a consistently high rate
of firing success when using the AS Meniscal Repair Device, in stark
comparison to other products on the market where I’ve experienced a
significant misfire rate. With an all-suture method of fixation, the AS
Meniscal Repair Device eliminates any migration risk of broken tacks or
anchors which could cause damage inside the knee and may lead to increased
operative time during removal. The AS Meniscal Repair Device has improved my
operative efficiency by delivering a high level of reliability and success.”

The new device, designed for intuitive use, works with only one thumb slide
actuation and no complex components. It also features clear, laser-etched
depth markings on the specially coated needles, allowing for precision in
depth of penetration. Needles are available in two configurations, curved and
straight, to meet surgeons’ diverse repair needs.

“Covidien is setting new standards for consistency and reliability with this
innovative, new design,” said Peter Marshall, Director of R&D, Covidien. “The
innovation seen in the design of the AS Meniscal Repair Device provides
orthopedic surgeons with the confidence and security of an all-suture repair
without the concern of rigid implant placement in soft tissue. Using feedback
from our surgeon customers, we designed the AS Meniscal Repair Device to
deliver optimal performance to address one of the fastest-growing orthopedic
procedures performed today.”

A torn meniscus is one of the most common injuries to the knee. According to a
recent market analysis conducted by Millennium Research Group^2, in 2010 more
than 840,000 procedures relating to meniscal injuries were performed in the
United States. Millennium’s research indicates that in the U.S., meniscus
repair procedures utilizing fixation devices are expected to increase at an
eight percent compound annual growth rate through 2015.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien manufactures, distributes
and services a diverse range of industry-leading product lines in three
segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012
revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70
countries, and its products are sold in over 140 countries. Please visit
www.covidien.com to learn more about our business.

^1 Bench top evaluation comparing the holding strength of the AS Meniscal
Repair Device pre-tied knot with high strength suture to a leading competitive
device (Covidien Test Report MRD-045 dated April 5, 2009); Bench top
evaluation measuring the fatigue strength of the AS Meniscal Repair Device
(Covidien Test Report MRD-024 dated May 14, 2009).

^2 US Markets for Orthopedic Soft Tissue Solutions 2011, Millennium Research
Group Inc. April 2011 at p. 133.

Contact:

Covidien
John Jordan, 508-452-4891
Manager, Communications
Surgical Solutions
john.jordan@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President, Communications
Surgical Solutions
marguerite.copel@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Director
Investor Relations
todd.carpenter@covidien.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement